指南与共识淋巴瘤

毛细胞白血病及变异型诊断与管理更新共识指南

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.
指南 / 共识 · Blood · 2026-01-01

国际毛细胞白血病基金会召集血液学专家更新2017年指南,总结HCL与HCLv的诊断和管理方法,并展望改善预后的新型靶向治疗。HCL多由BRAF-V600E突变驱动,对嘌呤类似物反应良好且适用BRAF抑制剂;HCLv无此突变,需嘌呤类似物联合利妥昔单抗且缓解持久性较差。

要点

  • HCL诊断需整合临床病理与BRAF-V600E检测,HCLv缺乏该突变。
  • HCL首选嘌呤类似物化疗,BRAF抑制剂为靶向选择。
  • HCLv需嘌呤类似物联合利妥昔单抗,缓解持久性较差。

核心结论

  • HCL与HCLv在遗传基础、预后和管理上不同,应分别制定诊断与治疗策略。

研究设计与样本

  • 国际毛细胞白血病基金会召集血液学专家更新2017年指南,总结诊断与管理方法并展望靶向治疗。

主要发现

  • HCL在>95%患者中由BRAF-V600E激酶激活突变引起,对嘌呤类似物化疗反应优秀且适用BRAF抑制剂靶向治疗。
  • HCLv缺乏BRAF-V600E突变,需嘌呤类似物联合利妥昔单抗,缓解通常不够持久。

临床怎么用

  • HCL应检测BRAF-V600E以指导嘌呤类似物或BRAF抑制剂治疗。
  • HCLv应采用嘌呤类似物联合利妥昔单抗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hairy cell leukemia (HCL) and HCL variant (HCLv) are distinct, rare, and chronic splenic B-cell lymphomas/leukemias that partially overlap in clinicopathologic presentation but differ in genetic basis, prognosis, and management. HCL is caused by the BRAF-V600E kinase-activating mutation in >95% of the patients, usually has excellent responses to chemotherapy with purine analogues, and is also amenable to BRAF inhibitor-based targeted treatments. In contrast, HCLv lacks BRAFV600E mutation, requires combined therapy with purine analogues in addition to rituximab, and generally shows less durable responses. Here, an international team of hematologists, experts on these rare diseases, was convened by the Hairy Cell Leukemia Foundation to update the previous guidelines (published in 2017) by providing a summary of current methods to diagnose and manage patients with HCL and HCLv as well as a prospective on newer targeted therapies to further improve outcomes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zent CS, Tiacci E, Kreitman RJ, et al. Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant. Blood. 2026. PMID: 41980020. doi:10.1182/blood.2025032757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。